The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

NCT05042336 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Carrelizumab Plus Lenvatinib Combined With TACE
Borderline Resectable Hepatocellular Carcinoma

Interventions

DRUG: camrelizumab/lenvatinib combined with TACE

Sponsor

Sichuan University